Status:
COMPLETED
Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Unresectable Stage III or IV Malignant Melanoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
The purpose of this study is to identify candidate markers predictive of response and/or serious toxicity to BMS-734016 (MDX-010).
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Histologic or cytologic diagnosis of unresectable State III or IV malignant melanoma (excluding ocular melanoma); A pre- and post-treatment fresh core or excision tumor biopsy must be provided.
Exclusion
Key Trial Info
Start Date :
November 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2007
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00261365
Start Date
November 1 2005
End Date
October 1 2007
Last Update
September 29 2016
Active Locations (15)
Enter a location and click search to find clinical trials sorted by distance.
1
Comprehensive Cancer Center
Palm Springs, California, United States, 92262
2
The Angeles Clinic And Research Institution
Santa Monica, California, United States, 90404
3
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States, 02215
4
Local Institution
Aarhus C, Denmark, 8000